Related Experiment Videos
Pentoxifylline treatment of moderate to severe chronic occlusive arterial disease
Insights
Pentoxifylline improved walking distance and reduced ischemic symptoms in patients with chronic occlusive arterial disease (COAD). This pilot study suggests pentoxifylline is a promising treatment for COAD, warranting further controlled trials.
Area of Science:
- Vascular Medicine
- Pharmacology
Background:
- Chronic occlusive arterial disease (COAD) significantly impacts patient mobility and quality of life.
- Current management strategies for moderate to severe COAD often have limitations.
Purpose of the Study:
- To evaluate the efficacy of pentoxifylline in patients with moderate to severe COAD.
- To assess the impact of pentoxifylline on exercise tolerance, ischemic symptoms, and vascular laboratory measurements.
Main Methods:
- Pilot study involving 19 patients with moderate to severe COAD.
- Open-label administration of pentoxifylline (1200 mg/day) for 12 weeks after a 2-week washout.
- Assessment of disease severity included walking distance, peripheral pulses, ankle-brachial index, and arteriography.
Main Results:
- Twelve of nineteen patients demonstrated increased exercise tolerance and reduced ischemic symptoms.
- The majority of patients (16/19) reported subjective benefit from pentoxifylline treatment.
- While subjective improvements were notable, objective vascular laboratory measurements showed only minor changes; however, platelet aggregation decreased.
Conclusions:
- Pentoxifylline shows potential as a therapeutic agent for managing moderate to severe chronic occlusive arterial disease.
- The observed improvements in exercise tolerance and symptoms justify further investigation through controlled clinical trials.
Abstract:
A pilot study of the effects of pentoxifylline in 19 patients with moderate to severe chronic occlusive arterial disease (COAD) is described. The severity of disease was assessed by the degree of limitation in the walking distance on the flat surface (less than 100 m), the absence of peripheral pulses on palpation, the diminished Doppler tibial/brachial pressure (the ischemic index) at rest, and by contrast arteriography, when available. After a 2-week washout phase, all subjects received pentoxifylline (1200 mg/day) in an open-label manner for a total of 12 weeks. Twelve of the nineteen patients showed a definite increase in exercise tolerance by the end of the study, with a concomitant reduction in ischemic symptoms. All except 3 patients felt they had derived benefit from the medication. In contrast to the clear improvements in walking distance and symptoms, only small effects on noninvasive vascular laboratory measurements were noted. Platelet aggregation, induced by ADP, epinephrine, and collagen, gradually decreased over the study period. Pentoxifylline appears to be useful in the medical management of patients with moderate to severe chronic occlusive arterial disease; future controlled trials in such patients are now justified.